SAN JOSE, Calif.--(BUSINESS WIRE)--Heart Repair Technologies, Inc. (“HRT” or “Company”), a privately-held medical device company specializing in disruptive mitral and tricuspid valve repair technology to resolve heart valve regurgitation in heart failure patients, today announced that David H. Chung has been appointed Chief Executive Officer (CEO), effective as of October 1, 2024..

加利福尼亚州圣何塞（商业新闻短讯）--心脏修复技术公司（“HRT”或“公司”）是一家私营医疗器械公司，专门从事破坏性二尖瓣和三尖瓣修复技术，以解决心力衰竭患者的心脏瓣膜反流，今天宣布任命David H.Chung为首席执行官（CEO），自2024年10月1日起生效。。

“David’s considerable experience in the heart valve space will be an invaluable asset to HRT as we prioritize an aggressive transcatheter development program,” said Rich Ferrari, Board Director at HRT. “With a strong background in early device development, operations and commercial expertise, we believe that David is the right leader to capitalize on HRT’s current momentum and drive our next phase of growth.”.

“David在心脏瓣膜领域的丰富经验将是HRT的宝贵资产，因为我们优先考虑积极的经导管开发计划，”HRT董事会董事RichFerrari表示。“凭借在早期设备开发、运营和商业专业知识方面的丰富背景，我们相信David是利用HRT当前势头并推动我们下一阶段增长的正确领导者。”。

Mr. Chung brings over 30 years of experience in the healthcare industry, particularly in the medtech and cardiovascular sectors, where he has a proven track record of leading global commercial organizations and guiding transformational growth. Prior to joining HRT, Mr. Chung most recently served as President and CEO of NeoChord, Inc., a transcatheter technology company specializing in the treatment of mitral valve prolapse.

钟先生在医疗保健行业拥有30多年的经验，特别是在医疗技术和心血管领域，他在领导全球商业组织和指导转型增长方面有着良好的业绩记录。在加入HRT之前，钟先生最近担任NeoChord，Inc.的总裁兼首席执行官，NeoChord，Inc.是一家专门治疗二尖瓣脱垂的经导管技术公司。

Additionally, from 2011-2012 he served as President and CEO of Mitralis, an early-stage mitral valve repair company. Chung began his career at Pfizer and later spent more than fifteen years at Edwards Lifesciences where he ultimately served as Vice President of North American Sales and Marketing for the Heart Valve Therapy Franchise and Global Vice President of Commercial Operations.

此外，2011-2012年，他担任二尖瓣早期修复公司Mitralis的总裁兼首席执行官。Chung在辉瑞开始了他的职业生涯，后来在爱德华兹生命科学公司（Edwards Lifesciences）工作了15年多，最终担任了心脏瓣膜治疗特许经营北美销售和营销副总裁和全球商业运营副总裁。

Chung received a Bachelor of Science in Engineering from the United States Military Academy at West Point and served as a PATRIOT Missile Officer in the United States Army with multiple distinctions, including recognition as an Operation Desert Storm Veteran and as an Airborne Badge and Bronze Star Medal recipient..

钟获得了美国西点军校工程理学学士学位，曾在美国陆军担任爱国者导弹军官，获得多项荣誉，包括沙漠风暴行动退伍军人、空降徽章和铜星奖章获得者。。

Dr. V.A. (Mani) Subramanian, Founder, Inventor and Board Director of HRT, added, “David is uniquely suited to lead the Company as we reach our next stage of development. HRT is preparing for the first-in-human study for our transcatheter mitral and tricuspid bridge devices, leveraging the long-term clinical success of our predicate, surgical device, which received CE Mark approval in 2017.

HRT的创始人、发明家和董事会主任V.A.（Mani）Subramanian博士补充说：“随着我们进入下一个发展阶段，David非常适合领导公司。HRT正在为我们的经导管二尖瓣和三尖瓣桥装置进行首次人体研究，利用我们的谓词手术装置的长期临床成功，该装置于2017年获得CE标志的批准。

It’s an exciting time in HRT’s story, and David is the obvious choice to lead the organization into our next stage.”.

在人力资源部的故事中，这是一个激动人心的时刻，大卫显然是领导该组织进入下一阶段的最佳人选。”。

“I am confident the Company’s differentiated technology with a transcatheter delivery will broadly reach the large, unmet patient population suffering from heart failure,” said David Chung. “I look forward to delivering on our strategic objectives as we advance the development of this device to a regulatory approval.”.

David Chung说：“我相信该公司通过经导管输送的差异化技术将广泛惠及大量未满足的心力衰竭患者。”。“随着我们将该设备的开发推进到监管部门的批准，我期待着实现我们的战略目标。”。

About Heart Repair Technologies, Inc.

关于心脏修复技术公司。

Heart Repair Technologies, Inc. (HRT) is a medical device company focused on the design, development and commercialization of innovative transcatheter solutions for the treatment of heart failure patients suffering from mitral and tricuspid regurgitation. The Company’s disruptive Trans Annular Bridge (TAB) System is designed to correct the core, clinical issue of a large central gap between the anterior and posterior annuli, while preserving native annular motion and subvalvular apparatus.

心脏修复技术公司（HRT）是一家医疗器械公司，专注于设计、开发和商业化创新的经导管解决方案，用于治疗患有二尖瓣和三尖瓣关闭不全的心力衰竭患者。该公司的破坏性跨环桥（TAB）系统旨在纠正前后环之间较大中心间隙的核心临床问题，同时保留天然环运动和瓣膜下装置。

The surgical version of the device received CE Mark approval for the mitral position, providing a strong clinical foundation for the development of the transcatheter delivery system. HRT is headquartered in San Jose, California..

该设备的外科版本获得了CE标志对二尖瓣位置的批准，为经导管输送系统的开发提供了强大的临床基础。HRT总部位于加利福尼亚州圣何塞。。